Radiopharm Theranostics Limited American Depositary Shares

Radiopharm Theranostics completed enrollment in its Phase 2b trial for RAD 101, an imaging agent for brain metastases, with interim data showing 90% concordance with MRI. The company also presented Phase 0/1 data for RAD 202 showing favorable safety and tumor uptake, received DSMC approval to advance to the next dose level, and initiated two new ...

Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to escalate its Phase 1 'HEAT' clinical trial of RAD202 to the next dose level of 130mCi in HER2-positive advanced solid tumor patients. The company remains on track to complete Phase 1 dose escalation by end of 2026.

Radiopharm Theranostics and Siemens Healthineers announced a supply agreement for RAD101, a novel PET imaging agent for brain metastases. The Phase 2b interim analysis showed 90% concordance with MRI (primary endpoint), with significant tumor uptake. Siemens will manufacture and distribute 18F-labeled RAD101 to support the upcoming Phase 3 regist...

Radiopharm Theranostics announced the first patient dosing in a Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer treatment. Preclinical data showed strong tumor targeting with minimal bone/marrow uptake. The company plans to share data from the first two dose level...

Radiopharm Theranostics announced interim Phase 2b results for RAD 101, with 92% of evaluable patients achieving the primary endpoint of MRI concordance in brain metastases imaging. The company also reported progress across its pipeline including DSMC approval for dose escalation in RAD 202 and RAD 204, FDA clearance for Phase 1 trials of RV 01 a...